Covax-19™ Uses, Dosage, Side Effects and more
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein. As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.
Trade Name | Covax-19™ |
Generic | Covax-19™ |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |